vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and TENNANT CO (TNC). Click either name above to swap in a different company.
TENNANT CO is the larger business by last-quarter revenue ($291.6M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -1.5%, a 14.9% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -11.3%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $9.7M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
The Tennant Company (TNC:NYQ) is a company with about 4000 employees that provides cleaning products. It is a company that is listed in the New York Stock Exchange.
AMPH vs TNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $291.6M |
| Net Profit | $24.4M | $-4.4M |
| Gross Margin | 46.8% | 34.6% |
| Operating Margin | 19.4% | -1.4% |
| Net Margin | 13.3% | -1.5% |
| Revenue YoY | -1.8% | -11.3% |
| Net Profit YoY | -35.7% | -166.7% |
| EPS (diluted) | $0.51 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $291.6M | ||
| Q3 25 | $191.8M | $303.3M | ||
| Q2 25 | $174.4M | $318.6M | ||
| Q1 25 | $170.5M | $290.0M | ||
| Q4 24 | $186.5M | $328.9M | ||
| Q3 24 | $191.2M | $315.8M | ||
| Q2 24 | $182.4M | $331.0M | ||
| Q1 24 | $171.8M | $311.0M |
| Q4 25 | $24.4M | $-4.4M | ||
| Q3 25 | $17.4M | $14.9M | ||
| Q2 25 | $31.0M | $20.2M | ||
| Q1 25 | $25.3M | $13.1M | ||
| Q4 24 | $38.0M | $6.6M | ||
| Q3 24 | $40.4M | $20.8M | ||
| Q2 24 | $37.9M | $27.9M | ||
| Q1 24 | $43.2M | $28.4M |
| Q4 25 | 46.8% | 34.6% | ||
| Q3 25 | 51.4% | 42.7% | ||
| Q2 25 | 49.6% | 42.1% | ||
| Q1 25 | 50.0% | 41.4% | ||
| Q4 24 | 46.5% | 41.3% | ||
| Q3 24 | 53.3% | 42.4% | ||
| Q2 24 | 52.2% | 43.1% | ||
| Q1 24 | 52.4% | 44.2% |
| Q4 25 | 19.4% | -1.4% | ||
| Q3 25 | 13.2% | 7.4% | ||
| Q2 25 | 24.2% | 9.6% | ||
| Q1 25 | 21.9% | 6.8% | ||
| Q4 24 | 24.2% | 2.3% | ||
| Q3 24 | 29.8% | 9.7% | ||
| Q2 24 | 30.3% | 11.7% | ||
| Q1 24 | 27.9% | 12.1% |
| Q4 25 | 13.3% | -1.5% | ||
| Q3 25 | 9.0% | 4.9% | ||
| Q2 25 | 17.8% | 6.3% | ||
| Q1 25 | 14.8% | 4.5% | ||
| Q4 24 | 20.4% | 2.0% | ||
| Q3 24 | 21.1% | 6.6% | ||
| Q2 24 | 20.8% | 8.4% | ||
| Q1 24 | 25.1% | 9.1% |
| Q4 25 | $0.51 | $-0.21 | ||
| Q3 25 | $0.37 | $0.80 | ||
| Q2 25 | $0.64 | $1.08 | ||
| Q1 25 | $0.51 | $0.69 | ||
| Q4 24 | $0.74 | $0.35 | ||
| Q3 24 | $0.78 | $1.09 | ||
| Q2 24 | $0.73 | $1.45 | ||
| Q1 24 | $0.81 | $1.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $273.2M |
| Stockholders' EquityBook value | $788.8M | $601.6M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | 0.77× | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $273.2M | ||
| Q3 25 | $608.6M | $238.3M | ||
| Q2 25 | $607.7M | $213.4M | ||
| Q1 25 | $603.9M | $213.3M | ||
| Q4 24 | $601.6M | $198.2M | ||
| Q3 24 | $596.4M | $208.6M | ||
| Q2 24 | $586.9M | $205.6M | ||
| Q1 24 | $594.0M | $207.4M |
| Q4 25 | $788.8M | $601.6M | ||
| Q3 25 | $776.7M | $640.9M | ||
| Q2 25 | $757.5M | $651.9M | ||
| Q1 25 | $751.3M | $624.4M | ||
| Q4 24 | $732.3M | $620.8M | ||
| Q3 24 | $727.7M | $647.2M | ||
| Q2 24 | $713.3M | $624.6M | ||
| Q1 24 | $672.4M | $614.6M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | 0.77× | 0.45× | ||
| Q3 25 | 0.78× | 0.37× | ||
| Q2 25 | 0.80× | 0.33× | ||
| Q1 25 | 0.80× | 0.34× | ||
| Q4 24 | 0.82× | 0.32× | ||
| Q3 24 | 0.82× | 0.32× | ||
| Q2 24 | 0.82× | 0.33× | ||
| Q1 24 | 0.88× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $14.2M |
| Free Cash FlowOCF − Capex | $24.6M | $9.7M |
| FCF MarginFCF / Revenue | 13.4% | 3.3% |
| Capex IntensityCapex / Revenue | 4.5% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $14.2M | ||
| Q3 25 | $52.6M | $28.7M | ||
| Q2 25 | $35.6M | $22.5M | ||
| Q1 25 | $35.1M | $-400.0K | ||
| Q4 24 | $29.0M | $37.5M | ||
| Q3 24 | $60.0M | $30.7M | ||
| Q2 24 | $69.1M | $18.6M | ||
| Q1 24 | $55.3M | $2.9M |
| Q4 25 | $24.6M | $9.7M | ||
| Q3 25 | $47.2M | $22.3M | ||
| Q2 25 | $25.0M | $18.7M | ||
| Q1 25 | $24.4M | $-7.4M | ||
| Q4 24 | $16.6M | $28.1M | ||
| Q3 24 | $46.2M | $26.4M | ||
| Q2 24 | $63.1M | $14.4M | ||
| Q1 24 | $46.5M | $-100.0K |
| Q4 25 | 13.4% | 3.3% | ||
| Q3 25 | 24.6% | 7.4% | ||
| Q2 25 | 14.3% | 5.9% | ||
| Q1 25 | 14.3% | -2.6% | ||
| Q4 24 | 8.9% | 8.5% | ||
| Q3 24 | 24.1% | 8.4% | ||
| Q2 24 | 34.6% | 4.4% | ||
| Q1 24 | 27.1% | -0.0% |
| Q4 25 | 4.5% | 1.5% | ||
| Q3 25 | 2.8% | 2.1% | ||
| Q2 25 | 6.1% | 1.2% | ||
| Q1 25 | 6.3% | 2.4% | ||
| Q4 24 | 6.7% | 2.9% | ||
| Q3 24 | 7.2% | 1.4% | ||
| Q2 24 | 3.3% | 1.3% | ||
| Q1 24 | 5.1% | 1.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.93× | ||
| Q2 25 | 1.15× | 1.11× | ||
| Q1 25 | 1.39× | -0.03× | ||
| Q4 24 | 0.76× | 5.68× | ||
| Q3 24 | 1.48× | 1.48× | ||
| Q2 24 | 1.82× | 0.67× | ||
| Q1 24 | 1.28× | 0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TNC
| Equipment Sales | $165.5M | 57% |
| Parts And Consumables | $69.1M | 24% |
| Service And Other | $57.0M | 20% |
